Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma

Completed · Phase 2

Conditions studied: Intraocular Melanoma, Melanoma (Skin)

In brief

RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining vaccine therapy with a monoclonal antibody may cause a stronger immune response and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy with monoclonal antibody therapy in treating patients who have stage IV melanoma.

Key facts

Study ID

NCT00032045

Run by

National Cancer Institute (NCI)

Starts

2002-01-01

Expected to finish

2006-08-01

Last updated by the study team

2013-06-20

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.